S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
S&P 500   5,078.18
DOW   38,972.41
QQQ   437.60
3 lithium stocks to ride a multi-year cycle
Is Gold Really Boring? (Ad)
Goldman upgraded Nvidia stock, one metric says it could go higher
Autozone stock price is still in the rally zone
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
New highs are coming for Lowe’s stock despite mixed results
Closing prices for crude oil, gold and other commodities
Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT? (Ad)
Consumer confidence slips in February as anxiety over potential recession surprisingly reappears
Beyond Meat's shares soar on better-than-expected Q4 revenue despite weak US sales
NASDAQ:NGM

NGM Biopharmaceuticals (NGM) Stock Price, News & Analysis

$1.63
+0.10 (+6.54%)
(As of 02/27/2024 ET)
Today's Range
$1.52
$1.64
50-Day Range
$0.86
$1.92
52-Week Range
$0.60
$4.83
Volume
5.85 million shs
Average Volume
806,462 shs
Market Capitalization
$134.83 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

NGM Biopharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
191.4% Upside
$4.75 Price Target
Short Interest
Healthy
4.11% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.54
Upright™ Environmental Score
News Sentiment
0.06mentions of NGM Biopharmaceuticals in the last 14 days
Based on 17 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.79) to ($1.13) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.42 out of 5 stars

Medical Sector

110th out of 944 stocks

Pharmaceutical Preparations Industry

35th out of 408 stocks


NGM stock logo

About NGM Biopharmaceuticals Stock (NASDAQ:NGM)

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 which is in phase I clinical trial for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck to focus primarily on the identification, research and development of collaboration compounds directed to targets in the fields of ophthalmology and cardiovascular or metabolic, or CVM, disease, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.

NGM Stock Price History

NGM Stock News Headlines

Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
NGM Bio To Be Acquired By Affiliates Of The Column Group, LP
NGM to go private through deal with investment firm
Is Gold Really Boring?
Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks.
NGM Biopharmaceuticals, Inc. (NGM)
NGM Biopharmaceuticals Inc NGM
See More Headlines
Receive NGM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NGM Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/27/2024
Next Earnings (Estimated)
2/27/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NGM
Fax
N/A
Employees
239
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$4.75
High Stock Price Target
$6.00
Low Stock Price Target
$3.50
Potential Upside/Downside
+191.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-162,670,000.00
Net Margins
-673.75%
Pretax Margin
-673.75%

Debt

Sales & Book Value

Annual Sales
$55.33 million
Book Value
$3.18 per share

Miscellaneous

Free Float
53,021,000
Market Cap
$134.83 million
Optionable
Optionable
Beta
1.27

Social Links

The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Mr. William J. Rieflin J.D. (Age 64)
    Executive Chairman of the Board of Directors
    Comp: $1.1M
  • Dr. David J. Woodhouse Ph.D. (Age 53)
    CEO & Director
    Comp: $860.75k
  • Ms. Valerie L. Pierce J.D. (Age 61)
    Senior VP, General Counsel, Secretary & Chief Compliance Officer
    Comp: $580.75k
  • Dr. Hsiao Dee Lieu F.A.C.C. (Age 54)
    M.D., Chief Medical Officer & Executive VP
    Comp: $625.75k
  • Jean Frederic Viret Ph.D.
    Chief Financial Officer
  • Ms. Irene Perlich
    VP, Corporate Controller & Principal Accounting Officer
  • Mr. Daniel Kaplan Ph.D.
    Chief Scientific Officer
  • Anthony Kuhlmann Ph.D.
    Head of Intellectual Property
  • Diana Peng Bockus
    Head of Business Development
  • Arthur Hsu Ph.D.
    Senior Director & Head of Biology














NGM Stock Analysis - Frequently Asked Questions

Should I buy or sell NGM Biopharmaceuticals stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NGM Biopharmaceuticals in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NGM shares.
View NGM analyst ratings
or view top-rated stocks.

What is NGM Biopharmaceuticals' stock price target for 2024?

2 Wall Street research analysts have issued 12-month target prices for NGM Biopharmaceuticals' stock. Their NGM share price targets range from $3.50 to $6.00. On average, they predict the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 191.4% from the stock's current price.
View analysts price targets for NGM
or view top-rated stocks among Wall Street analysts.

How have NGM shares performed in 2024?

NGM Biopharmaceuticals' stock was trading at $0.8590 at the beginning of the year. Since then, NGM stock has increased by 89.8% and is now trading at $1.63.
View the best growth stocks for 2024 here
.

When is NGM Biopharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NGM earnings forecast
.

How were NGM Biopharmaceuticals' earnings last quarter?

NGM Biopharmaceuticals, Inc. (NASDAQ:NGM) posted its quarterly earnings data on Thursday, November, 4th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by $0.03. The company had revenue of $18.58 million for the quarter, compared to analyst estimates of $18.90 million. NGM Biopharmaceuticals had a negative trailing twelve-month return on equity of 71.77% and a negative net margin of 673.75%.

What is David Woodhouse's approval rating as NGM Biopharmaceuticals' CEO?

3 employees have rated NGM Biopharmaceuticals Chief Executive Officer David Woodhouse on Glassdoor.com. David Woodhouse has an approval rating of 34% among the company's employees. This puts David Woodhouse in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did NGM Biopharmaceuticals IPO?

(NGM) raised $100 million in an initial public offering on Thursday, April 4th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Cowen served as the underwriters for the IPO.

Who are NGM Biopharmaceuticals' major shareholders?

NGM Biopharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.35%), Federated Hermes Inc. (0.42%), GSA Capital Partners LLP (0.40%), BNP Paribas Financial Markets (0.27%), Bridgeway Capital Management LLC (0.24%) and Dimensional Fund Advisors LP (0.19%). Insiders that own company stock include David J Woodhouse, David V Goeddel, Group L P Column, Hsiao D Lieu and Jin-Long Chen.
View institutional ownership trends
.

How do I buy shares of NGM Biopharmaceuticals?

Shares of NGM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NGM) was last updated on 2/28/2024 by MarketBeat.com Staff